![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Triazole antifungals are useful in the treatment of Aspergillus disease and these drugs have side effects which clinicians should be aware of. Posaconazole is an orally administered second-generation triazole antifungal agent which inhibits lanosterol 14-alpha-demethylase, an enzyme that converts lanosterol to ergosterol, a vital component of the fungal cell membrane. Posaconazole has a favorable side effect profile, is safe and well tolerated when compared to the earlier generation of triazole antifungals. Common side effects of posaconazole include gastrointestinal, hepatobiliary, neurological, and skin and subcutaneous disorders. Renal disorders are classed as an uncommon side effect of posaconazole, occurring in ∼0.1–1% of patients. We describe 2 episodes of acute kidney injury (AKI) in a Caucasian whose Aspergillus lung disease was being treated with posaconazole. Regular monitoring of renal function may be necessary for patients on posaconazole to facilitate early identification of acute kidney injury which is reversible.
Additional information
Notes on contributors
Akaninyene Otu
Akaninyene Otu is a Senior Clinical Fellow in Infectious Diseases at Manchester University NHS Foundation Trust. He also holds a Senior Lecturer position at the Department of Internal Medicine, University of Calabar, Nigeria.
Felix Bongomin
Felix Bongomin is a Clinical Research Associate at the National Aspergillosis Centre in Manchester.
Chris Kosmidis
Chris Kosmidis is a Senior Lecturer in Infectious Diseases and Honorary Consultant at Manchester University NHS Foundation Trust.
David W. Denning
David W. Denning is a Professor of Infectious Diseases in Global Health. He is also Director, National Aspergillosis Centre in Manchester and President, Global Action Fund for Fungal infections.